BioNeutral Group Completes Efficacy and Safety Testing of Ygiene Required for a Sporicide/Sterilant

BioNeutral Intends to Apply for US EPA Product Approval

BioNeutral Group, Inc. (OTCBB: BONU), a specialty chemical technology-based life science company, reports that yesterday it received final test results from ATS Labs indicating that its Ygiene™ Hospital Grade Antimicrobial has passed the stringent Sporicidal GLP test requirements for hospital and medical environment sporicide efficacy claims mandated by the US EPA. This key test demonstrates that Ygiene™ Hospital Grade Antimicrobial completely eliminates harmful spores. With the completion of this officially required GLP testing, BioNeutral is now positioned to apply for approval of its Ygiene™ Hospital Grade Antimicrobial as a bactericide, fungicide and sporicide with the US EPA. BioNeutral Group intends to proceed with these registrations in consultation with its advisors in order to move forward with the commercialization of its Ygiene™ Hospital Grade Antimicrobial.

Dr. Andy Kielbania, Chief Scientist at BioNeutral, stated: “We believe that these new test results show we have a superior sporicide compared to currently available products. With our approvals in the major European countries along with our previous results demonstrating sporicidal efficacy required for Canadian and Australian registration, we are now in a position to move forward in many of the major markets of the world.”

About ATS Labs
ATS Labs is a leading internationally recognized lab used by the developers and users of antimicrobial products. They provide comprehensive antimicrobial services and their superior client service and scientific data have earned them a distinguished record of acceptance with regulatory agencies in the US, Canada and the world.

About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a specialty chemical technology-based life science company that is developing and intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous microorganisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene™ and Ogiene™, are both eco-friendly. The Company has combined these widely used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have not yet been submitted to the EPA for approval for sale in the United States; however they have been approved in Germany and are allowed in the UK, France and Sweden.

Forward-Looking Statements
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.

Source: Business Wire/Yahoo Finance